29 October 2018

Polpharma listed among the largest Polish private companies yet again

Polpharma ranked seventh out of the 100 largest Polish private companies in a ranking list published by Forbes. According to the team behind the list, the total value of the top one hundred companies increased by PLN 12 billion as compared to last year. The list now includes 65 companies worth more than PLN 1 billion.

his is the third ranking list in the series published by Forbes.

“Forbes’s list of the 100 largest Polish private companies reflects the condition of the economy and the status of private businesses in Poland. I am delighted to see Polpharma among the top ten companies yet again. We are the leader of the Polish pharmaceutical market and a Polish national champion. As a private company, we can make decisions fast and introduce innovative solutions in a flexible way,” says Markus Sieger, CEO of Polpharma Group.

TOP 10 largest Polish private companies in 2018:

  1. Cyfrowy Polsat
  2. CD Projekt
  3. LPP
  4. CCC
  5. Dino Polska
  6. Synthos
  7. Polpharma
  8. Grupa Maspex
  9. Toruńskie Zakłady Materiałów Opatrunkowych
  10. Kruk

The full list of the most valuable private companies with Polish capital can be found in the latest issue of Forbes.

Ranking methodology:

Forbes’s ranking list includes the 100 largest Polish private companies. The ranking list and the methodology were developed in cooperation with Haitong Bank. The following criteria were applied in the ranking process to classify candidates as Polish companies:

a) A company whose majority stake is held by a Polish entrepreneur or a group of entrepreneurs acting jointly;

b) A company whose minority stake is held by a Polish entrepreneur, but who – nevertheless – actively manages or controls the company at a management or supervisory board level.

Enterprise value (EV) determined the company’s position in the ranking list. For companies not listed on the stock exchange (“WSE”), enterprise value was calculated by multiplying their EBIT by a valuation multiplier at an industry-specific rate. The calculation relied on the most recent financial data available for a full trading year (2015 or earlier). The value of equity capital, for indicative purposes, was calculated by subtracting the net debt value from the EV.

Read also

See all

Polpharma on its websites and mobile applications (“Website”) uses cookies and other related technologies (“cookies”). Self-management of cookies is possible by changing the settings in your web browser. If you do not agree to the collection of personal data through cookies, you can change the settings in your web browser or leave the Website.

By using the Website without changing the settings in your web browser, you accept Polpharma’s use of cookies. By accepting the settings in your web browser, you agree to profiling based on the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect the lawfulness of the processing that was carried out on the basis of consent before its withdrawal.

More information can be found in the Cookies Policy.